
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results.
ChemoCentryx reported quarterly losses of 58 cents per share which missed the analyst consensus estimate of a loss of 50 cents per share. ChemoCentryx also reported quarterly sales of $2.31 million which missed the analyst consensus estimate of $11.62 million by 80%. This is a 47% decrease over sales of $4.36 million in the same period last year.